A clinical trial involving cetrorelix was updated on June 25, 2026. The study, registered as NCT06572930, is titled "Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation." The trial's current status is listed as recruiting. No phase information was provided for this study. The trial focuses on serum FSH monitoring during ovarian stimulation, a context in which cetrorelix is an approved compound. No results have been posted for this trial at this time. The event data does not include information on trial design, participant numbers, or outcome measures beyond the study title and status. As recruitment continues, further updates may become available through the official clinical trial registry. Readers interested in this compound can refer to the compound overview for additional background and context. This brief reflects only the information provided in the trial record as of the update date and does not represent conclusions about safety or effectiveness.
Cetrorelix Featured in New Trial on FSH Monitoring in Stimulation
See the full cetrorelix overview
Source: https://clinicaltrials.gov/study/NCT06572930